VVOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vivos Therapeutics Inc (VVOS) is not a strong buy for a beginner, long-term investor at this time. While the company has shown significant revenue growth and improved net income in the latest quarter, the technical indicators are bearish, and there are no clear positive trading signals or strong catalysts to justify immediate investment. The stock may require further monitoring for better entry points.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 35.772, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.63, with key support at 1.455 and resistance at 1.804. Overall, the technical indicators suggest a bearish trend.
Analyst coverage from H.C. Wainwright initiated with a Buy rating and a $7 price target, citing potential sales growth from the company's new business model.
Gross margin dropped by 7.59% YoY, and the stock's technical indicators are bearish. There is no recent news or significant trading trends from hedge funds, insiders, or Congress to support a bullish sentiment.
In Q3 2025, revenue increased significantly to $6,783,000 (up 75.73% YoY), and net income improved to -$5,400,000 (up 106.42% YoY). EPS increased by 22.50% YoY to -0.49. However, gross margin dropped to 52.38%, down 7.59% YoY.
H.C. Wainwright initiated coverage with a Buy rating and a $7 price target, highlighting the company's potential for sales growth driven by its new business model and initiatives.
